IceCure Medical Regains Nasdaq Minimum Bid Price Compliance

Key Facts

In a move that removes the risk of delisting from Nasdaq, IceCure Medical (ICCM) has regained compliance with the exchange's minimum bid price requirement, according to the company's announcement on Friday. The stock's price rose above the required threshold, meeting Nasdaq's continued listing standards. This development is positive for the small-cap stock that had faced pressure due to non-compliance.

Per market data, ICCM closed at $7.02 on June 25, 2026, with trading ranging between $6.39 (low) and $8.44 (high). Regaining compliance follows a period of volatility that pushed the stock below the $1 minimum—a key condition for continued listing on Nasdaq. This milestone removes a major regulatory hurdle for the small-cap company, boosting investor confidence.

The company has not announced any new material developments following this news. The stock remains under investor watch for updates on financial performance or growth plans, given the absence of near-term calendar catalysts tied to ICCM. The removal of delisting risk could renew interest, but trading will depend on broader small-cap market sentiment.